Bal Pharma Limited (BOM:524824)

Market Cap	1.09B
Revenue (ttm)	2.95B
Net Income (ttm)	68.25M
Shares Out	15.92M
EPS (ttm)	4.29
PE Ratio	15.96
Forward PE	n/a
Dividend	1.20 (1.75%)
Ex-Dividend Date	Sep 18, 2025

Volume	159
Average Volume	3,605
Open	68.50
Previous Close	68.50
Day's Range	66.10 - 68.50
52-Week Range	66.10 - 128.86
Beta	0.20
RSI	31.69
Earnings Date	Feb 10, 2026

About Bal Pharma

Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic p...

• Industry: Pharmaceutical Preparations
• Founded: 1987
• Employees: 986
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 524824

Financial Performance

In 2024, Bal Pharma's revenue was 3.03 billion, a decrease of -10.65% compared to the previous year's 3.39 billion. Earnings were 72.15 million, a decrease of -2.39%.